<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698513</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-034</org_study_id>
    <nct_id>NCT03698513</nct_id>
  </id_info>
  <brief_title>A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects</brief_title>
  <official_title>A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Anti-thrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and interaction of BMS-986177 in healthy volunteers,
      when administered with Aspirin and/or Clopidogrel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Actual">February 19, 2019</completion_date>
  <primary_completion_date type="Actual">February 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 95</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to Day 33</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Cmax of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>AUC(TAU) of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>Tmax of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half-life (T-HALF)</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>T-Half of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough)</measure>
    <time_frame>Up to Day 26</time_frame>
    <description>Ctrough of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>CLT/F of BMS-986177, aspirin, clopidogrel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Up to Day 33</time_frame>
    <description>BMS-986177, aspirin, clopidogrel</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 4-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 placebo + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 placebo + Clopidogrel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 placebo + Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986177 + Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>BMS-986177 capsule</description>
    <arm_group_label>BMS-986177 (Part 1)</arm_group_label>
    <arm_group_label>BMS-986177 (Part 2)</arm_group_label>
    <arm_group_label>BMS-986177 (Part 3)</arm_group_label>
    <arm_group_label>BMS-986177 + Aspirin</arm_group_label>
    <arm_group_label>BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 + Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin tablet</description>
    <arm_group_label>BMS-986177 + Aspirin</arm_group_label>
    <arm_group_label>BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Aspirin</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Aspirin + Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel tablet</description>
    <arm_group_label>BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for BMS-986177)</intervention_name>
    <description>BMS-986177 placebo match capsule</description>
    <arm_group_label>BMS-986177 placebo + Aspirin</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>BMS-986177 placebo + Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive.

          -  Women not of childbearing potential (must have documented proof).

          -  Males who are sexually active with women of childbearing potential must agree to
             follow instructions for method(s) of contraception for the duration of treatment with
             BMS-986177 for a total of 92 days after completion of study treatment. Male
             participants must additionally refrain from sperm donation during this time.

        Exclusion Criteria:

          -  Women of childbearing potential or who are breastfeeding.

          -  Any significant acute or chronic medical illness, including tinnitus or any other
             condition listed as a contraindication in the aspirin package insert.

          -  History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for 1
             week's duration in the last month prior to study treatment administration).

          -  History of head injury in the last 2 years, including participants with base skull
             fractures, intracranial tumor, or aneurysm.

          -  History of gastroesophageal reflux disease, dyspepsia (indigestion), protracted
             nausea, or chronic diarrhea (defined as 3 or 4 loose stools per day that last for â‰¥ 4
             weeks) within the past 6 months.

          -  Any major surgery within 4 weeks of study treatment administration or planned within 2
             weeks after completion of the study.

          -  Use of tobacco- or nicotine-containing products (including, but not limited to,
             cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine
             lozenges, or nicotine gum) within 6 months prior to study treatment administration.

          -  History of any adverse reaction to anticoagulants or antiplatelet agents that resulted
             in excessive bleeding, requiring medication intervention.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Austin Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS clinical trial education resource</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

